ArticleFrontiers in oncology2026
Efficacy and safety of air-flow beds for autologous hematopoietic stem cell transplantation in multiple myeloma: a retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autologous hematopoietic stem cell transplantation (ASCT) is the standard consolidation therapy for multiple myeloma (MM), but its widespread implementation is constrained by the high cost and limited availability of conventional laminar airflow rooms. The air-flow bed, a single-bed unit equipped with high-efficiency particulate air (HEPA) filtration providing class 100 (ISO class 5) air quality, represents a more accessible and cost-effective alternative. Methods: In this retrospective cohort study, we compared the efficacy, safety, and costs of ASCT performed in air-flow beds (Group A, n=91) versus conventional laminar airflow rooms (Group B, n=60) in 151 MM patients treated between 2022 and 2026. Multivariable regression models were adjusted for potential confounders. Sepsis was analyzed descriptively because of the small number of events. Platelet transfusion requirements were analyzed using negative binomial regression. Results: Engraftment outcomes were comparable between groups. Group A showed significantly lower rates of mucositis, diarrhea, and nausea/vomiting, and no sepsis events occurred in Group A compared with four cases (6.7%) in Group B. Pathogen detection rate was lower in Group A than in Group B (5.5% vs. 15.0%, P = 0.050). In negative binomial regression, air-flow bed use was independently associated with a lower number of platelet transfusion units (IRR = 0.50, P<0.001). Higher CD34+ cell dose was also independently associated with fewer platelet transfusions (IRR = 0.94 per 1×10 Conclusion: These findings suggest that air-flow beds may represent a safe, effective, and economically viable alternative to conventional laminar airflow rooms for ASCT in MM. Because protective environment and transplant era were strongly intertwined, these observational associations should be interpreted with caution and regarded as hypothesis-generating. Prospective validation in randomized controlled trials is warranted to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.